A safety alert on CT scans and implantable electronic medical devices, such as insulin pumps, was issued by the FDA on April 1. ... Clinicians should then communicate this information to the facility performing the scan, the FDA said.
The Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing medications is being eliminated, the FDA announced on Dec. ... ensure that the benefits of the drugs outweigh their risks, according to an FDA safety alert.
This could cause it to fail to treat severe hypoglycemia due to loss of potency, the FDA said. ... consumer level due to loss of potency, the FDA announced on Sept.
class. The FDA is requiring safety labeling changes for fluoroquinolones to strengthen warnings that the antibiotics may cause significant decreases in blood glucose levels, as well as certain mental health side ... The new label changes will add an
https://diabetes.acponline.org/archives/2017/10/13/6.htm. A continuous glucose monitoring (CGM) system was approved and some infusion sets were recalled, the FDA recently announced. ... Approval was based on a study comparing readings from the device to
fail, the FDA recently warned. ... Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling, the FDA recently warned.
The FDA has permitted marketing of the Dermapace System, the first shock-wave device intended to treat diabetic foot ulcers, the agency announced on Dec.
FDA. The first generic version of pioglitazone hydrochloride (Actos) was recently approved to improve blood glucose control in adults with type 2 diabetes, along with diet and exercise. ... In addition, ranibizumab injection (Lucentis) received FDA
The FDA has removed the boxed warning about amputation risk from the prescribing information for canagliflozin (Invokana, Invokamet, Invokamet XR), the agency announced on Aug. ... monitored, the FDA decided to remove the boxed warning, according to the
https://diabetes.acponline.org/archives/2019/12/13/9.htm. The FDA is investigating whether metformin in the U.S. market contains N-nitrosodimethylamine. ... recalls at this time. The FDA is investigating whether metformin in the U.S.